Management of chronic pain. Part I

Disease-a-Month

Volumn 42, Issue 7, 1996, Pages 385-454

  Barkin, Stacy J ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b New Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CAPSAICIN; CARISOPRODOL; CHLORPROMAZINE; CLOMIPRAMINE; CLORAZEPATE DIPOTASSIUM; DESIPRAMINE; DIAZEPAM; DOXEPIN; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; IMIPRAMINE; LORAZEPAM; MAPROTILINE; METHOCARBAMOL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; PROTRIPTYLINE; SERTRALINE; THIORIDAZINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ANALGESIA; BEHAVIOR; CHRONIC PAIN; COGNITIVE THERAPY; CONFUSION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEPHROTOXICITY; NERVE BLOCK; REVIEW; SEIZURE;

EID: 0029837440     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(96)90017-6     Document Type: Review

References (242)

1. Pain clinic structure and function
2. Pharmacology, physiology and anesthetic implications of antidepressants
3. Rapid down regulation of p-adrenoceptors by co-administration of desipramine and fluoxetine
4. Transduction of receptor signal into modulation of effector activity by G proteins: the first 20 years or so
5. Signal-transducing G proteins and antidepressant drugs: evidence for modulation of a subunit gene expression in rat brain
6. Binding of antidepressants to human brain receptors: focus on newer generation compounds
7. MAOIs to RIMAs in anaesthesia: a literature review
8. Monoamine oxidase inhibitors and anesthesia: a review
9. Monoamine oxidase inhibitors revisited
10. MAO inhibitors and coronary artery surgery: a patient death
11. Monoamine oxidase inhibitors: should they be continued preoperatively?
12. Current status of tricyclic antidepressants in psychiatry: their pharmacology and clinical applications [symposium]
13. The pharmacologic treatment of depression
14. The medical consequences of the selection of an antidepressant
15. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease
16. Treating the depressed patient with cardiovascular problems
17. Adrenoceptors and their second messenger systems
18. 5-hydroxytryptamine receptors
19. Specific serotonin-uptake inhibitors and chronic pain: side-effects and long-term follow-up
20. Basic pharmacokinetic principles and their applications to psychotropic drugs
21. Pharmacologic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction
22. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline
23. The serotonin syndrome: implicated drugs, pathophysiology, and management
24. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors
25. Drugs and the treatment of psychiatric disorders
26. The clinical use of antipsychotic medications
27. Clozapine: a novel antipsychotic agent
28. Genitourinary and sexual adverse effects of psychotropic medication
29. The current status of neuroleptic therapy
30. The role of pimozide in clinical psychiatry: a review
31. Pimozide therapy for trigeminal neuralgia
32. Flumazenil: a new benzodiazepine antagonist
33. Antipsychotic medication
34. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
35. 1
36. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic Cozapine
37. Multiple dopamine D4 receptor variants in the human population [letter]
38. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia
39. The pharmacologic treatment of neuroleptic-induced akathisia
40. The neuroleptic malignant syndrome
41. Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics
42. Neuroleptic malignant syndrome: review of response to therapy
43. Mortality from neuroleptic malignant syndrome
44. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study
45. The neuroleptics as adjuvant analgesics
46. Risperidone: clinical safety and efficacy in schizophrenia
47. Tardive dyskinesia
48. Drug interactions with antipsychotic agents
49. Recognition assessment and treatment of anxiety in the critical care patient
50. Agrressive dyscontrol in patients treated with benzodiazepines
51. Central-type and peripheral-type benzodiazepine receptors
52. Flumazenil in benzodiazepine antagonism: actions and clinical use in intoxications and anaesthesiology
53. Anticonvulsant drugs and chronic pain
54. Benzodiazopines for acute pain in children
55. Midazolam: the first water-soluble benzodiazepine
56. Benzodiazopines and pain: effects of midazolam on the activities of nociceptive non-specific dorsal horn neurons in the rat spinal cord
57. An evaluation of the effects of zolpidem in patients with shortterm insomnia
58. Effects of chronically administered zolpidem on the sleep of healthy insomniacs
59. Dose-response of zolpidem in elderly patients with chronic insomnia [abstract]
60. Dose-response effects of zolpidem in normal geriatric subjects
61. Anticonvulsant drugs and chronic pain
62. Peripheral nerve disorders (peripheral neuropathies
63. Treatment of trigeminal neuralgia (tic douloureux)
64. Anti-convulsant drugs used in the treatment of lancinating pain: a comparison
65. Anticonvulsants in the therapy of neuralgic pain
66. Phenytoin in treatment of diabetic symmetrical polyneuropathy
67. Pain management in the patient with AIDS
68. Sensory motor neuropathy associated with AIDS
69. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex
70. Pain in HIV/AIDS
71. Pharmacological treatment of neuralgic and neuropathic pain
72. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain
73. Neuropathic pain
74. Can opiates relieve neuropathic pain?
75. Medical treatment and pharmacology of antiepileptic drugs
76. Time course of carbamazepine autoinduction
77. Absorption, distribution and excretion
78. Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control
79. Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia
80. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11,-epoxide: update
81. Adverse neuropsychiatric effects of anticonvulsants
82. Hepatotoxic reactions associated with carbamazepine therapy
83. Carbamazepine side effects in children and adults
84. Thrombocytopenia associated with carbamazepine: a case series
85. Carbamazepine and hematological monitoring
86. Carbamazepine-induced water intoxication: drugs that may increase the risk
87. Suppression of carbamazepine-induced rash with prednisone
88. Principles of clinically important drug interactions with carbamazepine. Part I
89. Principles of clinically important drug interactions with carbamazepine. Part II
90. Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration
91. Phenytoin as a coanalgesic in cancer pain
92. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin
93. Clinical response in epilepsy in relation to total and free serum levels of phenytoin
94. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy
95. Clinical rules for phenytoin dosing
96. Valproate: clinical use
97. Clinical pharmacokinetics of valproic acid, 1988
98. Adverse effects of valproate
99. Valproic acid hepatic fatalities: a retrospective review
100. Non-dose-related side effects of valproate
101. Valproate-associated pancreatitis
102. Valproic-acid associated pancreatitis: report of three cases and a brief review
103. Effect of valproate dose on formation of hepatotoxic metabolites
104. Long-term treatment with gabapentin for partial seizures
105. Gabapentin as an antiepileptic drug in man
106. Potential antiepileptic drugs: gabapentin
107. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma
108. Gabapentin in partial epilepsy
109. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study
110. Efficacy and safety of gabapentin (neurontin): a multicenter, placebo-controlled, double-blind study
111. Clonidine effect on spasticity: a clinical trial
112. Clonidine in pain management
113. Transdermal clonidine vs. placebo in painful diabetic neuropathy
114. Clonidine transdermal system for treatment of spasticity in spinal cord injury
115. Effect of transdermal clonidine on spinal spasticity: a case series
116. Postherapeutic neuralgia: a possible application for topical clonidine
117. Opiate withdrawal using clonidine: a safe, effective, and rapid nonopiate treatment
118. Clonidine and diabetic patients with leg pains
119. Is nociceptor activation by a,adrenoreceptors the culprit in sympathetically maintained pain?
120. Baclofen as an adjuvant analgesic
121. Baclofen decreases neurotransmitter release in mammalian CNS by action at novel GABA receptor
122. Baclofen (Lioresal) intoxication: report of 4 cases and review of literature
123. Neurosurgical treatment of spasticity: selective posterior rhizotomy and intrathecal baclofen
124. Intrathecal baclofen for intractable axial dystonia
125. Intrathecal drug administration: present use and future trends
126. Pharmacology of trigeminal neuralgia
127. Treatment of trigeminal neuralgia: use of baclofen in combination with carbamazepine
128. Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia
129. Baclofen in treatment of trigeminal neuralgia: double blind study and long-term follow-up
130. The new generation of serotonergic anxiolytics: possible clinical roles
131. The discovery and development of buspirone: a new approach to the treatment of anxiety
132. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study
133. Assessment of the abuse liability of buspirone in recreational sedative users
134. Serotonin-1A anxiolytics: an overview
135. Buspirone: an update on a unique anxiolytic agent
136. Treatment of painful diabetic neuropathy with topical capsaicin
137. Topical capsaicin treatment of chronic postherapeutic neuralgia
138. Post-herpetic neuralgia and topical capsaicin
139. Topical capsaicin in painful diabetic polyneuropathy
140. Substantia nigra: a site of action of muscle relaxant drugs
141. Conservative therapy for low back pain: distinguishing useful from useless therapy
142. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in lumbar region and neck: two double-blind controlled clinical and laboratory studies
143. Multiple morphine and enkephalin receptors and the relief of pain
144. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases
145. Treatment principles for the use of opioids in pain of nonmalignant origin
146. Opioids in chronic pain
147. Human pharmacology of narcotic antagonists
148. Multiple morphine and enkephalin receptors and the relief of pain
149. Clinical features and management of intoxication due to hallucinogenic drugs
150. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis
151. Clinical pharmacokinetics of morphine
152. Age and morphine analgesia in cancer patients with post-operative pain
153. Narcotics in the elderly
154. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites
155. Analgesic activity of morphine-6-glucoronide
156. Chronic nausea and morphine-6-glucoronide
157. Serum concentrations of morphine and its major metabolites after oral doses in normal volunteers and IV doses in renal failure
158. Plasma concentrations of morphine, morphine 3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to health volunteers: relationship to nonanalgesic actions
159. Considering histamine release in prescribing opioid analgesics
160. Opioids in chronic pain
161. Comparison of continuous subcutaneous and intravenous hydromorphone infusion for management of cancer pain
162. Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects
163. Problems with the use of oxycodone compound in patients with chronic pain
164. Clinical pharmacokinetics of pethidine
165. The effect of cirrhosis on the disposition and elimination of meperidine in man
166. Pharmacokinetic studies of meperidine
167. 1-acid glycoprotein and albumin
168. Normeperidine toxicity
169. Meperidine biotransformation and central nervous toxicity in animals and humans
170. Clinical pharmacokinetics of pethidine
171. Meperidine in patient controlled analgesia: a near fatal mishap
172. Central nervous system excitatory effects of meperidine in cancer patients
173. Meperdine-induced seizures in sickle cell patients
174. Monoamine oxidase inhibitors and narcotic analgesia: a critical review of the implications for treatment
175. Pharmacokinetics of levorphanol
176. Methadone use in the chronic cancer pain
177. The use of oral methadone to control moderate and severe pain in children and young adults with malignancy
178. Methadone use in patients with chronic renal disease
179. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients
180. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment
181. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain
182. Dextropropoxyphene kinetics after single and repeated oral doses in man
183. D-Propoxyphene kinetics after single oral and intravenous doses in man
184. Opioid agonist-antagonist drugs in acute and chronic pain states
185. Pentazocine: a review of its pharmacologic properties, therapeutics, efficacy and dependence liability
186. Abuse of pentazocine-naloxone combination
187. Bioavailability and first-pass metabolism of oral pentazocine in man
188. Seizures after pentazocine overdose
189. Buprenorphine kinetics
190. Human pharmacology and abuse potential of analgesic buprenorphine: Potential agent for treating narcotic addiction
191. Clinical pharmacokinetics of narcotic agonist-antagonist drugs
192. Buprenorphine detoxification from opioid dependence: pilot study
193. Buprenorphine suppresses heroin use by heroin addicts
194. Effect of modern analgesic drugs (tramadol, pentazocine, and buprenorphine) on the bile duct sphincter in man
195. Transnasal butorphanol: a new method for pain relief in postcesarean section pain
196. Respiratory and circulatory effects of intravenous butorphanol and morphine
197. Alternative agents in pharmacologic management of sickle cell pain crisis complicated by acute pancreatitis
198. Evaluation of new analgesics butorphanol and nalbuphine
199. Single and multiple-dose pharmacokinetics of dezocine in patients with acute and chronic pain
200. Nalbuphine: preliminary review of its pharmacological properties and therapeutic efficacy
201. Nasal polyps, bronchial asthma, and aspirin sensitivity: Samter syndrome
202. Lack of platelet effect with the aspirin analog salsalate
203. Acetaminophen hepatotoxicity in alcoholics
204. The morphine sparing effects of diclofenac sodium following abdominal surgery
205. Merits and liabilities of NSAID therapy
206. Another side effect of NSAIDS
207. NSAID-related adverse drug interactions with clinical relevance
208. Nonsteroidal anti-inflammatory drugs and peptic ulcers
209. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial
210. Focus on tramadol: a centrally acting analgesic for moderate to moderately severe pain
211. Alternative dosing for tramadol aids effectiveness
212. Mexiletine for treatment of chronic painful diabetic neuropathy
213. Mexiletine in the treatment of diabetic neuropathy
214. The analgesic effect of tocainide in trigeminal neuralgia
215. Subcutaneous lidocaine for treatment of neuropathic cancer pain
216. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy
217. Pain management and quality of life in cancer patients
218. MAO inhibitors and coronary artery surgery: a patient death
219. Transdermal fentanyl: suggested recommendations for clinical use
220. Ongoing activity in penpheral nerves: the physiology and pharmacology of impulses originating from a neuroma
221. Neurons that subserve sensory discriminative aspects of pain
222. Nerve root and spinal nerves in degenerative disease
223. Chemical irritation of the nerve root in disk prolapse
224. Epidural steroid injections for low back pain and lumbosacral radiculopathy
225. The role of epidural cortisone injection in the treatment of discogenic low back pain
226. A comparison between epidural anesthesia and bed rest in sciatica
227. The results of nonoperative treatment of ruptured lumbar disks